Responses to Docetaxel Plus Vinorelbine in Metastatic Breast Cancer
Author Information
Author(s): Andres R, Mayordomo J I, Isla D, Marti J L, Escudero P, Filipovich E, Saenz A, Alvarez I, Polo E, Tres A
Primary Institution: División of Medical Oncology, Hospital Clinco Universitario, Zaragoza, Spain
Hypothesis
Can docetaxel plus vinorelbine improve response rates in breast cancer patients who have relapsed after high-dose chemotherapy?
Conclusion
Docetaxel plus vinorelbine shows a promising response rate of 60% in heavily pretreated metastatic breast cancer patients.
Supporting Evidence
- 60% of patients responded to the treatment with docetaxel and vinorelbine.
- 14 patients had partial responses, and 4 had complete responses.
- Toxicity was manageable, with no severe neurotoxicity reported.
Takeaway
This study tested a new drug combination for breast cancer patients who didn't respond to previous treatments, and it worked for 60 out of 100 patients.
Methodology
30 patients were treated with docetaxel and vinorelbine, monitored for neurotoxicity and response rates.
Limitations
The study had a small sample size and a short follow-up period.
Participant Demographics
Median age was 48 years, with a range of 33 to 66 years; all patients had previously received anthracyclines.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website